Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In ArmaGen, Investors Seek A Brain-Penetrating Breakthrough

This article was originally published in Start Up

Executive Summary

For years, traditional VCs passed on ArmaGen’s technology that pulls drugs across the blood-brain barrier to reach previously undruggable targets. But in 2012, a syndicate of corporate investors obliged, suggesting they don’t mind losing their money if they can learn more about a difficult problem.

You may also be interested in...



Through the Palace Walls: Blood-Brain Barrier Transport Technologies

Delivering compounds across the blood-brain barrier remains the rate limiting step in brain-drug development, yet the problem generally gets ignored until it's too late. Several biotechs are bringing novel strategies to finding a solution, focusing especially on brain cancers. Success may open the floodgates of CNS drug development.

Craig Venter Wants To Extend Your Life (And Own Your Data)

The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.

Deals of the Week Takes Stock In M&A

Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092479

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel